Synthesis, biological evaluation and molecular modelling of new potent clickable analogues of 5-OP-RU for their use as chemical probes for the study of MAIT cell biology.


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
05 Feb 2021
Historique:
received: 30 09 2020
revised: 27 11 2020
accepted: 27 11 2020
pubmed: 21 12 2020
medline: 1 5 2021
entrez: 20 12 2020
Statut: ppublish

Résumé

MAIT cells are preset αβ T lymphocytes that recognize a series of microbial antigens exclusively derived from the riboflavin biosynthesis pathway, which is present in most bacteria. The most active known antigen is unstable 5-(2-oxopropylideneamino)-6-(d-ribitylamino)uracil (5-OP-RU) which is stabilized when bound and presented to MAIT cells by MHC-related protein 1 (MR1). Here we describe the chemical synthesis and biological evaluation of new chemical probes for the study of MAIT cell biology. The two probes were ethinyl functionalized analogues of 5-OP-RU able to react through CuAAC also called "click chemistry". The molecules up-regulated more MR1 than 5-OP-RU and they efficiently activated iVα19 Vβ8 TCR transgenic murine MAIT cells but not iVα19 TCRα transgenic MAIT cells indicating a surprisingly strong impact of the TRCβ chain. Moreover, the use of these molecules as chemical probes was validated in vitro by efficient and selective binding to MR1 revealed via fluorescence microscopy. This study was also complemented by molecular modelling investigation of the probes and the binary/ternary complexes they form with MR1 and the TCR. These new probes will be crucial to delineate the dynamics of 5-OP-RU at the cellular or whole organism level and to identify the cells presenting 5-OP-RU to MAIT cells in vivo.

Identifiants

pubmed: 33341648
pii: S0223-5234(20)31038-2
doi: 10.1016/j.ejmech.2020.113066
pii:
doi:

Substances chimiques

5-(2-oxopropylideneamino)-6-d-ribitylaminouracil 0
Ribitol 488-81-3
Uracil 56HH86ZVCT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113066

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Thomas Yvorra (T)

Institut Curie, PSL University, CNRS UMR3666, INSERM U1143, Paris, 75005, France.

Anke Steinmetz (A)

Centre de Recherche et Développement Vitry-Alfortville, IDD/ISDD, Sanofi-Aventis R&D, Vitry-sur-Seine, 94400, France.

Pascal Retailleau (P)

Institut de Chimie des Substances Naturelles, CNRS UPR 2301, Université Paris-Saclay, 1 Avenue de La Terrasse, Gif-sur-Yvette, 91190, France.

Olivier Lantz (O)

Institut Curie, PSL University, INSERM U932, Paris, 75005, France; Institut Curie, Laboratoire D'immunologie Clinique, Paris, 75005, France; Centre D'investigation Clinique en Biothérapie, Institut Curie (CIC-BT1428), Paris, 75005, France.

Frédéric Schmidt (F)

Institut Curie, PSL University, CNRS UMR3666, INSERM U1143, Paris, 75005, France. Electronic address: Frederic.Schmidt@curie.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH